Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 1 4Phase 2 2

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Conditions

Melanoma 42Carcinoma, Non-Small-Cell Lung 18Neoplasms 15Neoplasm Metastasis 14Carcinoma, Renal Cell 10Carcinoma, Hepatocellular 8Ovarian Neoplasms 6Colorectal Neoplasms 6Uveal Melanoma 5Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Pancreatic Neoplasms 5Mesothelioma 5Diabetes Mellitus, Insulin-Dependent, 12 5Carcinoma, Transitional Cell 5Squamous Cell Carcinoma of Head and Neck 4Sarcoma 4Lung Neoplasms 4Carcinoma, Merkel Cell 4Advanced Cancer 4Uterine Cervical Neoplasms 3Stomach Neoplasms 3Prostatic Neoplasms 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Liver Neoplasms 3Hodgkin Disease 3Head and Neck Neoplasms 3Carcinoma 3

Interventions

Nivolumab 9Ipilimumab 4linrodostat 2relatlimab 1regorafenib 1Tetanus Toxoid 1Sorafenib 1Paclitaxel 1Oxaliplatin 1N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 1Gemcitabine 1Cyclophosphamide 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Cancer × Ipilimumab × Clear all
NCT03459222 2026-04-06

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Bristol-Myers Squibb

Phase 1/2 Completed
229 enrolled 21 charts

Advanced Cancer

NCT03369223 2025-11-18

A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors

Bristol-Myers Squibb

Phase 1/2 Completed
356 enrolled 43 charts

Advanced Cancer

NCT03110107 2025-04-24

First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors

Bristol-Myers Squibb

Phase 1/2 Terminated
376 enrolled 56 charts

Advanced Cancer

NCT02737475 2022-01-25

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread

Bristol-Myers Squibb

Phase 1/2 Completed
166 enrolled 57 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡